FY2026 Q2 Financial Results (Material)
Filed with TSE · · 44 pages · English
Important Note on Future Events, etc This material has been prepared solely for the purpose of disclosing relevant information regarding HEALIOS K.K. (“HEALIOS”). This document does not constitute an offer to sell or the solicitation of an offer to buy any security in the United States, Japan or any other juri sdi ction. This presentation contains statements that constitute forward-looking stateme
Earlier from Healios KK
- Healios Selected for the AMED “Project to Promote the Industrialization of Regenerative/Cell Medicine and Gene Therapy”
- Notice Regarding the Filing of a Counterclaim in Response to a Lawsuit Filed Against Healios
- Healios K.K. to Present at Jefferies Global Healthcare Conference
- Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference
- Healios K.K. to Present at the 2025 Jefferies Global Healthcare Conference
Later from Healios KK
- Notice Regarding Shipment Timing of Initial Order of Culture Supernatant Products to JENECELL
- Shipment and Revenue Recognition of Initial Order of Culture Supernatant Products to JENECELL
Follow Healios KK into a list and get an email when it puts out news.
Follow Healios KK